The efficacy and safety of recombinant biosimilar growth hormone treatment in children with GHD and SGA: Czech retrospective national longitudinal study

M. Snajderova1, D. Zemkova1, Z. Sumnik2, J. Zapletalova2, R. Pomahacova3, S. Prahova1, J. Cermak1, B. Sadovska4
1Second Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
2Faculty of Medicine, Palacky University, Olomouc, Czech Republic
3Faculty of Medicine, Charles University, Pizen, Czech Republic
4Sandoz GmbH, Prague, Czech Republic

INTRODUCTION
Recombinant growth hormone (rhGH) treatment helps to achieve a final height close to the parental growth potential in children with GH deficiency (GHD) and small for gestational age (SGA).

Less is known about efficacy and safety of long term therapy with biosimilar rhGH.

AIM
- To assess height gain and safety of therapy with biosimilar rhGH (Omnitrope®, Sandoz) in Czech children enrolled into the PATRO Children study (Patient Treated with Omnitrope) with GHD and SGA over the first three years of treatment.
- To compare our effectiveness data with longitudinal international study GeNeSIS Italian Cohort (Humatrope®, Eli Lilly).

METHODS
- Patients were treated with rhGH Omnitrope® (Omnitrope®, Sandoz) by the dose recommended for GHD 0.025–0.035 mg/kg/day, and for SGA 0.035 mg/kg/day.
- Auxological data to assess height gain were compared with published data of GeNeSIS study.
- Adverse events (AEs) were analysed as well (questionnaire data).

RESULTS

Our data confirm significant improvement of growth parameters and safety of therapy with biosimilar rhGH Omnitrope® in Czech children with GHD and SGA which is consistent with results from international database GeNeSIS study.

Safety of therapy

The side effects were in most cases in both the GHD and SGA cohorts of mild intensity. Their association with GH treatment was unlikely. These included (in some cases recurrent) acute respiratory infections, diarrhea, urinary tract infections, and trauma (Fracture of the arm and leg). GH therapy was interrupted for a short time in 2 children with GHD (acute infection) and in 1 SGA subject (trauma).

- No cases of serious adverse events associated with GH treatment were observed in the GHD and SGA cohorts.
- No cancer, headache, edema, hypertension, asthma, diabetes mellitus or other serious problems were observed during follow-up.

CONCLUSIONS

REFERENCES


CONTACT INFORMATION
marta.snajderova@lfmotol.cuni.cz

ACKNOWLEDGEMENTS

The authors thank Prof. J. Lobi, Dr. M. Dvorakova, Dr. I. Cermakova, Dr. J. Skvor, Dr. O. Magnova, Dr. J. Cerna, Dr. J. Strnadel, and Dr. I. Plasilova for the investigation and regular monitoring of Czech children included into the PATRO-Children study.

Table 1. Characteristics of cohort.

<table>
<thead>
<tr>
<th>Patients</th>
<th>n</th>
<th>n100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male</td>
<td>n</td>
<td>42/103</td>
</tr>
<tr>
<td>Idiopathic GHD</td>
<td>n</td>
<td>100</td>
</tr>
<tr>
<td>SGA</td>
<td>n</td>
<td>65</td>
</tr>
</tbody>
</table>

Table 2. Data in GeNeSIS study1 compared with PATRO Czech study (3 year cohort).

<table>
<thead>
<tr>
<th>Number</th>
<th>GHD</th>
<th>PATRO Cz</th>
<th>SGA/UGR</th>
<th>PATRO Cz</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDS at baseline</td>
<td>median (range)</td>
<td>median (range)</td>
<td>median (range)</td>
<td>median (range)</td>
</tr>
<tr>
<td>Age</td>
<td>9.8 (9.3 - 10.1)</td>
<td>7.2 (6.6 - 8.3)</td>
<td>9.9 (6.4 - 10.4)</td>
<td>6.3 (5.5 - 7.1)</td>
</tr>
<tr>
<td>Height velocity</td>
<td>4.8 (4.1 - 5.6)</td>
<td>4.2 (4.5 - 5.0)</td>
<td>4.1 (3.9 - 5.0)</td>
<td>4.7 (4.0 - 5.8)</td>
</tr>
<tr>
<td>Height velocity SDS</td>
<td>-1.2 (-1.6 to -0.9)</td>
<td>-2.9 (-2.8 to -1.2)</td>
<td>-1.3 (-2.2 to -0.3)</td>
<td>-1.8 (-2.6 to -1.04)</td>
</tr>
<tr>
<td>Growth velocity</td>
<td>-2.4 (-2.5 to -2.3)</td>
<td>-2.9 (-3.0 to -2.7)</td>
<td>-2.9 (-3.5 to -2.4)</td>
<td>-3.0 (-3.5 to -2.4)</td>
</tr>
<tr>
<td>GH dose mg/kg/week</td>
<td>0.23 (0.22 - 0.24)</td>
<td>0.23 (0.2 to 0.23)</td>
<td>0.23 (0.19 - 0.27)</td>
<td>0.25 (0.24 - 0.26)</td>
</tr>
<tr>
<td>Duration of GH therapy (months (meanSD))</td>
<td>46.2 ± 19.2</td>
<td>45.9 ± 21.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Number of patients with adverse events related and probably unrelated to GH treatment, number of adverse events (AEs) in Czech GHD and SGA cohort.

| Subjects with AEs related to GH therapy | 0 |
| Subjects with AEs probably unrelated to GH therapy | 23 (23) |
| Number of AEs | 51 |

Growth data

- No cases of serious adverse events associated with GH treatment were observed in both the GHD and SGA cohorts.
- No cancer, headache, edema, hypertension, asthma, diabetes mellitus or other serious problems were observed during follow-up.

Fig 1. Body height (SDS) in all pre-pubertal Czech children included to PATRO Children study (A) and the difference between current and target height SDS during 3 years of follow-up: GHD and SGA cohort (B).

Fig 2. Incidence and intensity of adverse events (AEs), all probably unrelated to GH therapy in the Czech cohort during follow-up.

Fig 3. Comparison of current and target height SDS during 3 years of follow-up: GHD and SGA cohort.

Fig 4. Comparison of current and target height SDS during 3 years of follow-up: GHD and SGA cohort.

Fig 5. Comparison of current and target height SDS during 3 years of follow-up: GHD and SGA cohort.

ACKNOWLEDGEMENTS

The authors thank Prof. J. Lobi, Dr. M. Dvorakova, Dr. I. Cermakova, Dr. J. Skvor, Dr. O. Magnova, Dr. J. Cerna, Dr. J. Strnadel, and Dr. I. Plasilova for the investigation and regular monitoring of Czech children included into the PATRO-Children study.